Publication

Does Neoadjuvant FOLFOX Chemotherapy Improve the Prognosis of High-Risk Stage II and III Colon Cancers? Three Years Follow-up Results of the PRODIGE 22 Phase II Randomized Multicentre Trial

ANNÉE

2021

AUTEURS

Karoui M, Gallois C, Piessen G, Legoux JL, Barbier E, De Chaisemartin C, Lecaille C, Bouche O, Ammarguellat H, Brunetti F, Prudhomme M, Regimbeau JM, Glehen O, Lievre A, Portier G, Hartwig J, Goujon G, Romain B, Lepage C, Taieb J, for PRODIGE 22 investigators/Collaborators

CONGRÈS/REVUE

Colorectal Dis

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1111/codi.15585

Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child-Pugh B cirrhosis

ANNÉE

2021

AUTEURS

Blanc JF, Khemissa F, Bronowicki JP, Monterymard C, Perarnau JM, Bourgeois V, Obled S, Abdelghani MB, Mabile-Archambeaud I, Faroux R, Seitz JF, Locher C, Senellart H, Villing AL, Audemar F, Costentin C, Deplanque G, Manfredi S, Edeline J, PRODIGE 21 collaborators

CONGRÈS/REVUE

Hepatol Int

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1007/s12072-020-10120-3

Locoregional relapses in the ACCORD 12/0405-PRODIGE 02 study: Dosimetric study and risk factors

ANNÉE

2021

AUTEURS

Meillan N, Orthuon A, Chauchat P, Atlani D, Bouche O, Chaulin B, David C, Deberne M, Debrigode C, Kao W, Keller A, Laharie H, Lamezec B, Lemanski C, Magné N, Mahé MA, Mere P, Moureau-Zabotto L, Peiffert D, Pointreau Y, Quéro L, Racadot S, Roca S, Sargos P, Servagi S, Tang E, Vendrely V, Doyen J, Huguet F

CONGRÈS/REVUE

Radiother Oncol

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1016/j.radonc.2021.06.006

Targeting HGF/c-Met Axis Decreases Circulating Regulatory T Cells Accumulation in Gastric Cancer Patients

ANNÉE

2021

AUTEURS

Palle J, Hirsch L, Lapeyre-Prost A, Malka D, Bourhis M, Pernot S, Marcheteau E, Voron T, Castan F, Lacotte A, Benhamouda N, Tanchot C, François E, Ghiringhelli F, de la Fouchardière C, Zaanan A, Tartour E, Taieb J, Terme M

CONGRÈS/REVUE

Cancers (Basel)

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.3390/cancers13215562

Impact of Laparoscopy on Oncological Outcomes after Colectomy for Stage III Colon Cancer: A Post-Hoc Multivariate Analysis from PETACC8 European Randomized Clinical Trial

ANNÉE

2021

AUTEURS

Voron T, Karoui M, Lo Dico R, Malicot K L, Espin E, Cianchi F, Jürgen W, Buggenhout A, Bruzzi M, Denimal F, Cazelles A, Douard R, Lepage C, Taieb J

CONGRÈS/REVUE

Dig Liver Dis

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1016/j.dld.2021.05.012

Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial

ANNÉE

2020

AUTEURS

Aparicio T, Bennouna J, Le Malicot K, Boige V, Taieb J, Bouche O, Phelip JM, Francois E, Borel C, Faroux R, Dahan L, Bachet JB, Egreteau J, Kaminsky MC, Gornet JM, Cojocarasu O, Gasmi M, Guerin-Meyer V, Lepage C, Ghiringhelli F

CONGRÈS/REVUE

Br J Cancer

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1038/s41416-020-0735-8

Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma

ANNÉE

2020

AUTEURS

Niogret J, Limagne E, Thibaudin M, Blanc J, Bertaut A, Le Malicot K, Rinaldi Y, Caroli-Bosc FX, Audemar F, Nguyen S, Sarda C, Lombard-Bohas C, Locher C, Carreiro M, Legoux JL, Etienne P.-L, Baconnier M, Porneuf M, Aparicio T, Ghiringhelli F

CONGRÈS/REVUE

Cancers (Basel)

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.3390/cancers12061429

Impact of time-varying cumulative bevacizumab exposures on survival: re-analysis of data from randomized clinical trial in patients with metastatic colo-rectal cancer

ANNÉE

2020

AUTEURS

Guilloteau A, Abrahamowicz M, Boussari O, Jooste V, Aparicio T, Quantin C, Le Malicot K, Binquet C

CONGRÈS/REVUE

BMC Med Res Methodol

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1186/s12874-020-01202-9

Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III study

ANNÉE

2020

AUTEURS

Manfredi S, Turpin A, Malka D, Barbier E, Laurent-Puig P, Zaanan A, Dahan L, Lièvre A, Phelip JM, Michel P, Hautefeuille V, Legoux JL, Lepage C, Tougeron D, Aparicio T

CONGRÈS/REVUE

Dig Liver Dis

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1016/j.dld.2020.06.034

Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA:The CIRCULATE-PRODIGE 70 trial

ANNÉE

2020

AUTEURS

Taïeb J, Benhaim L, Laurent Puig P, Le Malicot K, Emile JF, Geillon F, Tougeron D, Manfredi S, Chauvenet M, Taly V, Lepage C, André T

CONGRÈS/REVUE

Dig Liver Dis

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1016/j.dld.2020.04.010